Ignite Creation Date:
2024-05-06 @ 7:24 AM
Last Modification Date:
2024-10-26 @ 11:48 AM
Study NCT ID:
NCT02525939
Status:
COMPLETED
Last Update Posted:
2022-10-12
First Post:
2015-08-13
Brief Title:
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
Sponsor:
DalCor Pharmaceuticals
Organization:
DalCor Pharmaceuticals
Organization Data
Organization:
DalCor Pharmaceuticals
Class:
INDUSTRY
Study ID:
DAL-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
DalCor Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Roche Molecular Systems Inc | INDUSTRY |
| The Montreal Health Innovations Coordinating Center MHICC | OTHER |
| Medpace Inc | INDUSTRY |